Kalpit Patel
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
50
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBPH Longboard Pharmaceuticals | Downgrades: Neutral | $45 → $60 | $59.69 | +0.52% | 4 | Oct 14, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $16.92 | +136.41% | 2 | Sep 20, 2024 | |
| BCYC Bicycle Therapeutics | Downgrades: Neutral | $33 → $28 | $22.71 | +23.29% | 5 | Aug 7, 2024 | |
| VSTM Verastem | Maintains: Buy | $21 → $7 | $3.92 | +78.57% | 3 | Jul 24, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $46.47 | -22.53% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $1.14 | +163.16% | 2 | Jun 18, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $11 → $9 | $3.20 | +181.25% | 4 | Jun 12, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Neutral | $25 → $20 | $22.28 | -10.23% | 3 | May 9, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $13 | $14.20 | -11.97% | 3 | Mar 6, 2024 | |
| XFOR X4 Pharmaceuticals | Downgrades: Neutral | $3 → $1 | $0.52 | +92.68% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $6.17 | -2.76% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $18.98 | +89.67% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.11 | +21.65% | 2 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.29 | +947.49% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.72 | +561.76% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.80 | +177.78% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.37 | +1,543.84% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $10 | $0.71 | +1,310.44% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $4.18 | +1,694.26% | 2 | Sep 3, 2021 |
Longboard Pharmaceuticals
Oct 14, 2024
Downgrades: Neutral
Price Target: $45 → $60
Current: $59.69
Upside: +0.52%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $16.92
Upside: +136.41%
Bicycle Therapeutics
Aug 7, 2024
Downgrades: Neutral
Price Target: $33 → $28
Current: $22.71
Upside: +23.29%
Verastem
Jul 24, 2024
Maintains: Buy
Price Target: $21 → $7
Current: $3.92
Upside: +78.57%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $46.47
Upside: -22.53%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.14
Upside: +163.16%
PDS Biotechnology
Jun 12, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $3.20
Upside: +181.25%
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $22.28
Upside: -10.23%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $13
Current: $14.20
Upside: -11.97%
X4 Pharmaceuticals
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.52
Upside: +92.68%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $6.17
Upside: -2.76%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $18.98
Upside: +89.67%
Mar 20, 2023
Reiterates: Buy
Price Target: $5
Current: $4.11
Upside: +21.65%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.29
Upside: +947.49%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.72
Upside: +561.76%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.80
Upside: +177.78%
Jun 7, 2022
Maintains: Buy
Price Target: $12 → $6
Current: $0.37
Upside: +1,543.84%
Jan 24, 2022
Maintains: Buy
Price Target: $24 → $10
Current: $0.71
Upside: +1,310.44%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $4.18
Upside: +1,694.26%